Medtronic and Covidien: An Attractive Investment?
Yesterday's news was all about Medtronic's proposed transaction with Covidien . But let's take a brief look at whether this tie-up implicates Medtronic as a potentially attractive investment. Of course, there were already reasons to like Medtronic -- it has significant exposure to international and emerging markets, and don't forget that the slow-growing med-tech behemoth is a dividend aristocrat (with at least 25 consecutive years of dividend increases to earn that designation). So, do the shares look attractive?
In the video below, health care analysts Michael Douglass and David Williamson give their thoughts on the investing case for Medtronic.
Top dividend stocks for the next decade -- is Medtronic one?
Dividend aristocrats like Medtronic are particularly impressive, because after all the smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
The article Medtronic and Covidien: An Attractive Investment? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Covidien. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.